The new study, published in Circulation, represents a collaboration between specialists from a variety of facilities, including Cleveland Clinic and the University of Arizona. 

The Impella RP System is still associated with significant benefits, the FDA said, but there are certain high-risk patients who should no longer be eligible for treatment.

Getinge has provided a detailed breakdown of the shortage, stating that it is not yet clear when it may be over. The FDA said it will keep a close eye on the situation and provide updates when possible. 

Watch our exclusive interview, recorded live at the AHA Scientific Sessions 2022 conference, with three investigators from the BEST-CLI trial. 

A randomized study of more than 450 patients with persistent atrial fibrillation is now underway. All patients have been treated, and their outcomes will be tracked for 12 months. 

The ACC is especially excited to see what VR training can do to bring minimally invasive interventional procedures to more and more patients throughout the United States.